Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Breast - Female" returned 7 results:


Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers
Principal Investigator(s): Elisa Port

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without LY2835219, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Principal Investigator(s): Dr. Amy Tiersten

A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Principal Investigator(s): Dr. Amy Tiersten

A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive,
Principal Investigator(s): Amy Tiersten

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Principal Investigator(s): Paul Hank Schmidt

Phase I/II Trial of Ruxolitinib in combination with Trastuzumab in Metastatic Her2 positive breast cancer
Principal Investigator(s): Dr. Amy Tiersten

NSABP Protocol B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Traztuzumab in Women with Node-Positive or High Risk Node Negative HER2-Low Invasive Breast Cancer
Principal Investigator(s): Amy Tiersten